These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Kantarjian H; Oki Y; Garcia-Manero G; Huang X; O'Brien S; Cortes J; Faderl S; Bueso-Ramos C; Ravandi F; Estrov Z; Ferrajoli A; Wierda W; Shan J; Davis J; Giles F; Saba HI; Issa JP Blood; 2007 Jan; 109(1):52-7. PubMed ID: 16882708 [TBL] [Abstract][Full Text] [Related]
7. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Wijermans PW; Rüter B; Baer MR; Slack JL; Saba HI; Lübbert M Leuk Res; 2008 Apr; 32(4):587-91. PubMed ID: 17881052 [TBL] [Abstract][Full Text] [Related]
9. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Aribi A; Borthakur G; Ravandi F; Shan J; Davisson J; Cortes J; Kantarjian H Cancer; 2007 Feb; 109(4):713-7. PubMed ID: 17219444 [TBL] [Abstract][Full Text] [Related]
10. Adult hematopoiesis is regulated by TIF1γ, a repressor of TAL1 and PU.1 transcriptional activity. Kusy S; Gault N; Ferri F; Lewandowski D; Barroca V; Jaracz-Ros A; Losson R; Romeo PH Cell Stem Cell; 2011 Apr; 8(4):412-25. PubMed ID: 21474105 [TBL] [Abstract][Full Text] [Related]
11. Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia. Carr RM; Patnaik MM Curr Opin Hematol; 2020 Jan; 27(1):2-10. PubMed ID: 31688455 [TBL] [Abstract][Full Text] [Related]
12. SMG1 acts as a novel potential tumor suppressor with epigenetic inactivation in acute myeloid leukemia. Du Y; Lu F; Li P; Ye J; Ji M; Ma D; Ji C Int J Mol Sci; 2014 Sep; 15(9):17065-76. PubMed ID: 25257528 [TBL] [Abstract][Full Text] [Related]
13. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737 [TBL] [Abstract][Full Text] [Related]
14. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management. Parikh SA; Tefferi A Am J Hematol; 2013 Nov; 88(11):967-74. PubMed ID: 23963888 [TBL] [Abstract][Full Text] [Related]
16. How I treat chronic myelomonocytic leukemia. Solary E; Itzykson R Blood; 2017 Jul; 130(2):126-136. PubMed ID: 28572287 [TBL] [Abstract][Full Text] [Related]
17. Hypermethylation of the 5' CpG island of the FHIT gene is associated with hyperdiploid and translocation-negative subtypes of pediatric leukemia. Zheng S; Ma X; Zhang L; Gunn L; Smith MT; Wiemels JL; Leung K; Buffler PA; Wiencke JK Cancer Res; 2004 Mar; 64(6):2000-6. PubMed ID: 15026336 [TBL] [Abstract][Full Text] [Related]
18. TiF1-gamma plays an essential role in murine hematopoiesis and regulates transcriptional elongation of erythroid genes. Bai X; Trowbridge JJ; Riley E; Lee JA; DiBiase A; Kaartinen VM; Orkin SH; Zon LI Dev Biol; 2013 Jan; 373(2):422-30. PubMed ID: 23159334 [TBL] [Abstract][Full Text] [Related]